{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:03:14Z","timestamp":1794553394423,"version":"4.9.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the proportion of patients in remission and low disease activity (LDA) between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Outpatient record data of 100 patients with SLE and of 100 matched patients with seropositive RA, with at least three consecutive outpatient visits each between August 2021 and January 2023 were compared. Documentation at every visit included SLE Disease Activity Index 2000 (SLEDAI-2K) for SLE, Simplified Disease Activity Index (SDAI) for RA and visual analogue scales (VAS). Remission and LDA were defined by SDAI cut-offs in RA and Definition of Remission in SLE (DORIS) remission and Lupus Low Disease Activity State (LLDAS) in SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Remission or LDA were present in 347 (88.5%) of 392 visits of SLE and 354 (91.0%) of 389 visits of RA patients (P\u2009=\u20090.2885). Remission was more common in SLE (79.3%) than RA (69.4%) data points (P\u2009=\u20090.0018). Physician global assessment (PhGA) was not significantly different between SLE and RA patients in low disease activity, and only slightly higher in SLE in remission (P\u2009=\u20090.0002). C-reactive protein (CRP) was increased (P\u2009=\u20090.0107) but the erythrocyte sedimentation rate was similar in active RA vs active SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treat-to-target (T2T) goals were similarly met for SLE and RA patients on current treatment. Despite differences between the diseases and according to differences in definitions, these data suggest that the SLE definitions for remission and LDA were successfully modelled on those of RA. The rates with which favourable states were noted support the T2T approach in SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag045","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:39:00Z","timestamp":1769171940000},"source":"Crossref","is-referenced-by-count":2,"title":["Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis"],"prefix":"10.1093","volume":"65","author":[{"given":"Konrad","family":"H\u00fcther","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, and Interdisciplinary University Center for Autoimmune and Rheumatic Entities (UCARE), Faculty of Medicine and University Medical Center at the TU Dresden , Dresden,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Leuchten","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, and Interdisciplinary University Center for Autoimmune and Rheumatic Entities (UCARE), Faculty of Medicine and University Medical Center at the TU Dresden , Dresden,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, and Interdisciplinary University Center for Autoimmune and Rheumatic Entities (UCARE), Faculty of Medicine and University Medical Center at the TU Dresden , Dresden,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026021306011927200_keag045-B1","article-title":"A glimpse into the future of systemic lupus erythematosus","volume":"14","author":"Aringer","year":"2022","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"2026021306011927200_keag045-B2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/ker368","article-title":"Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort","volume":"51","author":"Lopez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2026021306011927200_keag045-B3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B5","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021306011927200_keag045-B6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2026021306011927200_keag045-B7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021306011927200_keag045-B8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B9","doi-asserted-by":"crossref","first-page":"102356","DOI":"10.1016\/j.jaut.2019.102356","article-title":"Evolving story of autoantibodies in systemic lupus erythematosus","volume":"110","author":"Pisetsky","year":"2020","journal-title":"J Autoimmun"},{"key":"2026021306011927200_keag045-B10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026021306011927200_keag045-B11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1177\/09612033241299978","article-title":"Fibromyalgia, mood disorders and chronic damage are the main determinants of worse quality of life in systemic lupus erythematosus patients: results from a cross-sectional analysis","volume":"33","author":"Ceccarelli","year":"2024","journal-title":"Lupus"},{"key":"2026021306011927200_keag045-B12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B13","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/art.42645","article-title":"Association between severe nonadherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC inception cohort","volume":"75","author":"Nguyen","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026021306011927200_keag045-B14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/rheumatology\/keae344","article-title":"Long-term outcomes of childhood-onset systemic lupus erythematosus","volume":"64","author":"Mirguet","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026021306011927200_keag045-B15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/keu413","article-title":"Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review","volume":"54","author":"Navarro-Comp\u00e1n","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2026021306011927200_keag045-B16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.20105","article-title":"Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis","volume":"62","author":"Radovits","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026021306011927200_keag045-B17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"2026021306011927200_keag045-B20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026021306011927200_keag045-B22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B23","first-page":"S112","article-title":"Treat-to-target in systemic lupus erythematosus: where are we today?","volume":"30(Suppl 73)","author":"Mosca","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026021306011927200_keag045-B24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B25","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026021306011927200_keag045-B26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B27","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026021306011927200_keag045-B28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000516","article-title":"LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial","volume":"8","author":"Mucke","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026021306011927200_keag045-B29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026021306011927200_keag045-B31","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026021306011927200_keag045-B32","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2026021306011927200_keag045-B34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.berh.2007.02.004","article-title":"The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care","volume":"21","author":"Aletaha","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026021306011927200_keag045-B35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/annrheumdis-2016-209489","article-title":"Remission in systemic lupus erythematosus: durable remission is rare","volume":"76","author":"Wilhelm","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/annrheumdis-2016-210154","article-title":"The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients","volume":"76","author":"Zen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/rheumatology\/key349","article-title":"The relationship between remission and health-related quality of life in a cohort of SLE patients","volume":"58","author":"Tsang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026021306011927200_keag045-B38","doi-asserted-by":"crossref","first-page":"102502","DOI":"10.1016\/j.jaut.2020.102502","article-title":"SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients","volume":"112","author":"Zen","year":"2020","journal-title":"J Autoimmunity"},{"key":"2026021306011927200_keag045-B39","doi-asserted-by":"crossref","first-page":"e528-36","DOI":"10.1016\/S2665-9913(24)00121-8","article-title":"Association of sustained lupus low disease activity state with improved outcomes in SLE: a multinational prospective cohort study","volume":"6","author":"Golder","year":"2024","journal-title":"The Lancet Rheumatol"},{"key":"2026021306011927200_keag045-B40","doi-asserted-by":"crossref","first-page":"e001336","DOI":"10.1136\/lupus-2024-001336","article-title":"Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)","volume":"12","author":"Aringer","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026021306011927200_keag045-B41","doi-asserted-by":"crossref","first-page":"e004387","DOI":"10.1136\/rmdopen-2024-004387","article-title":"Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data","volume":"10","author":"Duarte","year":"2024","journal-title":"RMD open"},{"key":"2026021306011927200_keag045-B42","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026021306011927200_keag045-B43","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026021306011927200_keag045-B44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00393-025-01646-8","article-title":"Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany","volume":"84","author":"Albrecht","year":"2025","journal-title":"Z Rheumatol"},{"key":"2026021306011927200_keag045-B45","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1093\/rheumatology\/keaf281","article-title":"Type I interferon limits interleukin-6 signaling in SLE through shedding interleukin-6 receptors","volume":"64","author":"Hempel","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag045\/66564666\/keag045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag045\/66564666\/keag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag045\/66564666\/keag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:01:29Z","timestamp":1770980489000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag045\/8440148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag045","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,29]]},"article-number":"keag045"}}